| George Chaucer Hwang, MD | |
|
3800 Reservoir Rd Nw, Department Of Internal Medicine, Washington, DC 20007-2113 | |
| (202) 444-2600 | |
| Not Available |
| Full Name | George Chaucer Hwang |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 15 Years |
| Location | 3800 Reservoir Rd Nw, Washington, District Of Columbia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306071592 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD041583 (District Of Columbia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Medstar Georgetown University Hospital | Washington, DC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Medstar Medical Group Anesthesiology Llc | 1052678034 | 456 |
| Medstar Medical Group Anesthesiology Llc | 1052678034 | 456 |
News Archive
Researchers have successfully created miniature organoid brains in the labs that when attached to a spinal cord and muscles could help move the muscles.
Missing bones after an accident? Arteries destroyed by disease? An international team of DCU researchers have begun work on ways of producing synthetic hard and soft tissue for humans that could revolutionise treatment for people affected by disease and trauma.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
When cholesterol-clogged plaque narrows an artery that feeds the heart, the body responds by trying to bulk up tiny blood vessels in the heart.
Michael Pulsipher, MD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, along with co-principal investigator, Sung-Yun Pai, MD, of Boston Children's Hospital, has been awarded nearly $9 million from the National Institute of Allergy and Infectious Diseases of the NIH to study a new treatment approach for babies born with severe combined immunodeficiency (SCID) which prevents the immune system from functioning normally.
› Verified 1 days ago
| Entity Name | Medstar Medical Group Anesthesiology Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528578333 PECOS PAC ID: 1052678034 Enrollment ID: O20171129001837 |
News Archive
Researchers have successfully created miniature organoid brains in the labs that when attached to a spinal cord and muscles could help move the muscles.
Missing bones after an accident? Arteries destroyed by disease? An international team of DCU researchers have begun work on ways of producing synthetic hard and soft tissue for humans that could revolutionise treatment for people affected by disease and trauma.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
When cholesterol-clogged plaque narrows an artery that feeds the heart, the body responds by trying to bulk up tiny blood vessels in the heart.
Michael Pulsipher, MD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, along with co-principal investigator, Sung-Yun Pai, MD, of Boston Children's Hospital, has been awarded nearly $9 million from the National Institute of Allergy and Infectious Diseases of the NIH to study a new treatment approach for babies born with severe combined immunodeficiency (SCID) which prevents the immune system from functioning normally.
› Verified 1 days ago
| Entity Name | Anesthesia Connections-virginia, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922337930 PECOS PAC ID: 6608166335 Enrollment ID: O20190327000278 |
News Archive
Researchers have successfully created miniature organoid brains in the labs that when attached to a spinal cord and muscles could help move the muscles.
Missing bones after an accident? Arteries destroyed by disease? An international team of DCU researchers have begun work on ways of producing synthetic hard and soft tissue for humans that could revolutionise treatment for people affected by disease and trauma.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
When cholesterol-clogged plaque narrows an artery that feeds the heart, the body responds by trying to bulk up tiny blood vessels in the heart.
Michael Pulsipher, MD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, along with co-principal investigator, Sung-Yun Pai, MD, of Boston Children's Hospital, has been awarded nearly $9 million from the National Institute of Allergy and Infectious Diseases of the NIH to study a new treatment approach for babies born with severe combined immunodeficiency (SCID) which prevents the immune system from functioning normally.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| George Chaucer Hwang, MD 3800 Reservoir Rd Nw, Department Of Internal Medicine, Washington, DC 20007-2113 Ph: (202) 444-2600 | George Chaucer Hwang, MD 3800 Reservoir Rd Nw, Department Of Internal Medicine, Washington, DC 20007-2113 Ph: (202) 444-2600 |
News Archive
Researchers have successfully created miniature organoid brains in the labs that when attached to a spinal cord and muscles could help move the muscles.
Missing bones after an accident? Arteries destroyed by disease? An international team of DCU researchers have begun work on ways of producing synthetic hard and soft tissue for humans that could revolutionise treatment for people affected by disease and trauma.
Cellectar, Inc., a privately held radiopharmaceutical company that designs and develops products to detect, treat and monitor human cancers, today announced that enrollment for its Phase I dosimetry trial for its lead drug candidate, (131)I-CLR1404 has been completed. Results of this trial will be used to set the starting dose in a follow-on Phase I dose escalation study planned for later this year. Institutions that participated in the trial include City of Hope, Duke University Medical Center, Georgetown University/Lombardi Cancer Center, and Johns Hopkins Hospital.
When cholesterol-clogged plaque narrows an artery that feeds the heart, the body responds by trying to bulk up tiny blood vessels in the heart.
Michael Pulsipher, MD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, along with co-principal investigator, Sung-Yun Pai, MD, of Boston Children's Hospital, has been awarded nearly $9 million from the National Institute of Allergy and Infectious Diseases of the NIH to study a new treatment approach for babies born with severe combined immunodeficiency (SCID) which prevents the immune system from functioning normally.
› Verified 1 days ago
Dr. Fay Horng, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7504 | |
Dr. Matthew Mueller, DO, MPH Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 110 Irving St Nw, Washington, DC 20010 Phone: 202-877-7000 | |
Dr. Shane Zamani, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 900 23rd St Nw, Washington, DC 20037 Phone: 202-715-4750 | |
Dr. Thomas Edward Borsari, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 50 Irving St Nw, Dept Of Anesthesiology, Washington, DC 20422 Phone: 202-745-8000 | |
Alexis Lambros, CAA Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-476-2025 | |
Susan Verghese, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 111 Michigan Ave Nw, Washington, DC 20010 Phone: 202-884-2025 | |
Joan Threlfall, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3800 Reservoir Rd Nw, Washington, DC 20007 Phone: 202-444-8640 |